Trancriptomic characterization of labetuzumab effect on IL13-treated human bronchial epithelial cells. Trancriptomic characterization of labetuzumab effect on IL13-treated human bronchial epithelial cells

We have characterized the effect of the CEACAM5 targeting monoclonal antibody labetuzumab (2 µg/mL) on the transcriptional response to interleukin-13 (IL-13) treatment (10ng/mL) of air-liquid interface (ALI) cultures generated from primary human bronchial epithelial cells. ALI cultures were treated with IL-13 and labetuzumab during the last 7 days of ALI development and the transcriptomes analyzed by RNA-seq. Overall design: We analyzed the transcriptomes of 12 ALI cultures divided in 3 experimental groups: untreated control ALIs ( no IL-13, no labetuzumab), IL-13 treated ALIs and ALIs treated with both IL-13 and labetuzumab.

本研究表征了靶向癌胚抗原相关细胞黏附分子5 (CEACAM5) 的单克隆抗体拉贝珠单抗 (labetuzumab，2 µg/mL)，对原代人支气管上皮细胞构建的气液界面 (air-liquid interface, ALI) 培养物经白细胞介素-13 (interleukin-13, IL-13，10ng/mL) 处理后的转录应答影响。实验过程中，在ALI培养体系发育的最后7天，分别对ALI培养物施加IL-13单独处理、拉贝珠单抗联合IL-13处理，并通过RNA测序 (RNA-seq) 分析其转录组。整体实验设计如下：本研究共纳入12组ALI培养物进行转录组分析，分为3个实验组：未处理对照组（无IL-13、无拉贝珠单抗）、仅经IL-13处理组，以及IL-13与拉贝珠单抗联合处理组。